16.88 USD
↘ 0.18 (1.05%)AT CLOSE (AS OF 07:31 PM EDT)
Bicara Therapeutics Inc. Common Stock
BCAXNASDAQ • USD
Market: CLOSED
Bicara Therapeutics Inc. Common Stock (BCAX) is currently trading at $16.88. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest BCAX is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Oct 26, 2026.
Open?$16.98
High?$17.67
Low?$16.44
Prev. Close?$17.07
Volume?1.1M
Avg. Volume?797.8K
VWAP?$16.80
Rel. Volume?1.32x
Bid / Ask
Bid?$14.14 × 100
Ask?$19.17 × 100
Spread?$5.03
Midpoint?$16.66
Valuation & Ratios
Market Cap?1.1B
Shares Out?66.2M
Float?43.2M
Float %?65.2%
P/E Ratio?N/A
P/B Ratio?2.41
EPS?-$2.80
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Themes
Address
116 HUNTINGTON AVENUE SUITE 703
BOSTON, MA 02116
Phone: 617-468-4219
BOSTON, MA 02116
Phone: 617-468-4219
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?23
Short Sent.?39
Piotroski F-Score?0/9Weak
Altman Z-Score?14.08Safe
Confidence?41%Low
Short InterestSqueeze Risk
Short % of Float?23.85%Squeeze Risk
Short Interest?10.3M
Days to Cover?11.5
Free Float43.2M
Avg Daily Volume893.3K
Settlement Date2026-10-15
Financial Health
Current Ratio?11.59Strong
Quick Ratio?11.59Strong
Cash Ratio?2.22Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?2.41CHEAP▾
Peers100
S&P66
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-5.1CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-39.5%WEAK▾
S&P3
ROA?-36.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-135248000
Enterprise Value?$1.0B
Fundamentals ratios updated end of day